Trexquant Investment LP Buys Shares of 42,144 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Trexquant Investment LP purchased a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACADFree Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 42,144 shares of the biopharmaceutical company’s stock, valued at approximately $1,320,000.

Other large investors also recently made changes to their positions in the company. Jump Financial LLC lifted its stake in shares of ACADIA Pharmaceuticals by 326.3% during the 4th quarter. Jump Financial LLC now owns 116,341 shares of the biopharmaceutical company’s stock worth $3,643,000 after purchasing an additional 89,053 shares during the period. M&G Investment Management Ltd. purchased a new position in shares of ACADIA Pharmaceuticals in the 4th quarter worth $10,349,000. Mutual of America Capital Management LLC purchased a new position in shares of ACADIA Pharmaceuticals in the 4th quarter worth $2,206,000. Qube Research & Technologies Ltd raised its position in shares of ACADIA Pharmaceuticals by 757.2% in the 3rd quarter. Qube Research & Technologies Ltd now owns 212,919 shares of the biopharmaceutical company’s stock worth $4,437,000 after buying an additional 188,080 shares during the period. Finally, RTW Investments LP raised its position in shares of ACADIA Pharmaceuticals by 18.3% in the 3rd quarter. RTW Investments LP now owns 11,576,537 shares of the biopharmaceutical company’s stock worth $241,255,000 after buying an additional 1,793,288 shares during the period. Hedge funds and other institutional investors own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Stock Down 0.7 %

Shares of ACAD stock opened at $15.09 on Wednesday. The business has a 50 day moving average of $16.84 and a two-hundred day moving average of $22.47. ACADIA Pharmaceuticals Inc. has a 52 week low of $14.65 and a 52 week high of $33.99. The company has a market cap of $2.49 billion, a P/E ratio of -1,509.00 and a beta of 0.42.

ACADIA Pharmaceuticals (NASDAQ:ACADGet Free Report) last released its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.06. The company had revenue of $205.83 million for the quarter, compared to analysts’ expectations of $208.31 million. ACADIA Pharmaceuticals had a negative return on equity of 0.41% and a negative net margin of 0.21%. The business’s revenue for the quarter was up 73.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.27) earnings per share. Analysts expect that ACADIA Pharmaceuticals Inc. will post 0.57 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ACAD has been the topic of several research reports. HC Wainwright cut their price objective on ACADIA Pharmaceuticals from $33.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, May 9th. Stifel Nicolaus cut their price objective on ACADIA Pharmaceuticals from $26.00 to $21.00 and set a “hold” rating on the stock in a research report on Thursday, May 9th. Robert W. Baird cut their price objective on ACADIA Pharmaceuticals from $31.00 to $28.00 and set an “outperform” rating on the stock in a research report on Thursday, May 9th. Bank of America cut their price objective on ACADIA Pharmaceuticals from $26.00 to $22.00 and set a “neutral” rating on the stock in a research report on Friday, May 10th. Finally, Citigroup lowered their target price on ACADIA Pharmaceuticals from $30.19 to $30.00 and set a “buy” rating for the company in a research note on Thursday, May 9th. Four investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $28.94.

Check Out Our Latest Research Report on ACADIA Pharmaceuticals

Insider Activity

In other news, CEO Stephen Davis sold 17,714 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $17.90, for a total transaction of $317,080.60. Following the sale, the chief executive officer now owns 118,842 shares of the company’s stock, valued at $2,127,271.80. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, CEO Stephen Davis sold 17,714 shares of the business’s stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $17.90, for a total transaction of $317,080.60. Following the sale, the chief executive officer now owns 118,842 shares of the company’s stock, valued at $2,127,271.80. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Mark C. Schneyer sold 5,434 shares of the business’s stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $17.90, for a total value of $97,268.60. Following the sale, the chief financial officer now directly owns 26,183 shares in the company, valued at approximately $468,675.70. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 81,669 shares of company stock valued at $1,441,922. Insiders own 28.30% of the company’s stock.

ACADIA Pharmaceuticals Profile

(Free Report)

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.

Featured Stories

Institutional Ownership by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.